GlassScriptPhysician profile
Brian M Brinegar
NPI 1821181751
$33,224.68
in general payments reported to CMS, 2019-2025
37 companies · $6,149 in 2025
The $6,149 reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,520 · 2022: $3,018 · 2023: $12K · 2024: $9,498 · 2025: $6,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $11K · Consulting Fee: $2,260 · Travel and Lodging: $1,294 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $12,565.00 |
| Food and Beverage | $11,392.26 |
| Consulting Fee | $2,260.00 |
| Travel and Lodging | $1,293.94 |
| Education | $174.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $14,922.27 | 2022-2024 | Vtama |
| Pfizer INC. | $2,407.03 | 2021-2025 | |
| Abbvie INC. | $1,595.62 | 2021-2025 | |
| Janssen Biotech, INC. | $1,585.69 | 2021-2025 | Tremfya, Simponi, Stelara |
| Incyte Corporation | $1,419.25 | 2021-2025 | Opzelura |
| Ucb, INC. | $1,331.36 | 2021-2025 | Bimzelx |
| Galderma Laboratories, L.P. | $1,310.65 | 2021-2025 | Nemluvio, Aklief, Epsolay |
| Sun Pharmaceutical Industries INC. | $1,272.77 | 2021-2025 | Winlevi, Absorica Ld, Ilumya |
| Verrica Pharmaceuticals INC. | $1,000.00 | 2024 | Ycanth |
| Regeneron Healthcare Solutions, INC. | $990.01 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $848.02 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $735.92 | 2021-2025 | Jublia |
| Lilly USA, LLC | $670.25 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Journey Medical Corporation | $550.08 | 2022-2025 | |
| Leo Pharma INC. | $494.22 | 2021-2025 | Adbry, Anzupgo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $410.25 | 2022-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $302.22 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $243.42 | 2023-2025 | Zoryve |
| Organon LLC | $238.71 | 2025 | Vtama, Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $185.32 | 2022-2024 | Sotyktu |
| Kyowa Kirin, INC. | $132.29 | 2021-2025 | Poteligeo |
| Genzyme Corporation | $124.68 | 2021-2025 | |
| Epi Health, LLC | $93.38 | 2021-2022 | |
| Botanix Sb INC | $54.12 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $51.76 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.98 | 2023-2025 | Spevigo, Cyltezo |
| Fresenius Kabi USA, LLC | $32.30 | 2023 | |
| Integra Lifesciences Corporation | $28.66 | 2024 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Organogenesis INC. | $21.57 | 2025 | Puraply Wound Matrix |
| Biofrontera INC. | $18.41 | 2021 | |
| Dermira, INC. | $18.33 | 2021 | |
| Lnhc, INC | $17.83 | 2025 | Zelsuvmi |
| Paratek Pharmaceuticals, INC. | $17.53 | 2025 | Nuzyra |
| Medimetriks Pharmaceuticals, INC. | $16.50 | 2022 | |
| Almirall LLC | $16.29 | 2022 | |
| Mimedx Group, INC. | $14.90 | 2025 | |
| Nabriva Therapeutics, Plc | $14.09 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Brinegar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.